Document is current
Any future updates will be listed below
-
Authors
Gomez-Llobell, Marina https://orcid.org/0009-0002-3116-0915
Serra Smith, Carlos
Gómez-Costas, Daniel
Gómez-Centurión, Ignacio
García Domínguez, Jose Manuel
Escudero-Vilaplana, Vicente
Fernández Bullido, Yolanda
Carbonell, Diego https://orcid.org/0000-0003-2960-0301
Pion, Marjorie
Bailén, Rebeca https://orcid.org/0000-0003-2838-1776
Gil-Perotin, Sara
Martínez Ginés, María Luisa
Revuelta-Herrero, José Luis
Fernández-Caldas, Paula
Fernández, Verónica Astrid Pérez
Collado-Borrell, Roberto
Bastos-Oreiro, Mariana https://orcid.org/0000-0002-9431-4646
Villanueva-Bueno, Cristina
García-Sanz, Ramón
-
Funding
Funding for this research was provided by:
Sociedad Española de Hematología y Hemoterapia (SEHH-CRIS)
Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (PI23/01037 (ISCIII))
- License Information
-
More Information
Article History
Received: 4 March 2025
Revised: 18 June 2025
Accepted: 8 July 2025
First Online: 24 July 2025
Competing interests
: MK reports compensation for consultancy services from AbbVie, Incyte, and Sanofi, as well as speaker’s bureau fees from Novartis, Pfizer, and Takeda. MBO reports compensation that includes honoraria and board fees from Roche, Novartis, BMS, AbbVie, Kite, and Incyte, as well as research funding from Kite, AbbVie, and Incyte. MLMG reports compensation for consulting services and speaking fees from Merck, Biogen, Novartis, Sanofi, Almirall, BMS, J&J, ROCHE, Amgen, Horizon, AstraZeneca, Neuraxpharm and Viatri. SG-P has received speaker honoraria from Sanofi, Roche, Merck, and Biogen and has participated on Merck and Bristol Myers Squibb advisory boards.
